Complete response in a melanoma patient treated with imatinib

Journal of Laryngology and Otology

Volumn 126, Issue 6, 2012, Pages 638-640

  Brown, M C ^a   Casasola, R J ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Antineoplastic Agents; C kit Protein; Melanoma; Nasopharynx; Proto Oncogenes

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EXON; FOLLOW UP; GENE MUTATION; HUMAN; MALE; MELANOMA; MOLECULAR GENETICS; NASOPHARYNX MELANOMA; NASOPHARYNX TUMOR; ONCOGENE C KIT; PRIMARY TUMOR; RHINORRHEA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; EXONS; GENE EXPRESSION; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84861808857     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215112000527     Document Type: Article

References (17)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 1998;83:1664-78
2. Cancer Research UK. Skin cancer - UK incidence statistics. In: http://info.cancerresearchuk.org/cancerstats/types/skin/incidence [29 November 2010]
3. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18: 3782-93
4. Rivera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27-32
5. Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405
6. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F et al. Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11
7. Kim KB, Eton O, DavisDW, Frazier ML, McConkey DJ, Diwan AH et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-40
8. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet- derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45
9. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
10. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3
11. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34
12. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731-41
13. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22: 1446-56
14. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24: 4340-6
15. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8
16. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008;14:7726-32
17. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-94